Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication

Virology Journal

Volumn 2, Issue , 2005, Pages 1-12

  Zhu, Haizhen ^a   Butera, Mike ^a   Nelson, David R ^a   Liu, Chen ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON IL 28A; COMPLEMENTARY DNA; GENOMIC DNA; HLA ANTIGEN CLASS 1; INTERFERON; INTERFERON RECEPTOR; INTERLEUKIN 10; JANUS KINASE; STAT PROTEIN; UNCLASSIFIED DRUG; VIRUS RNA;

ANTIGEN EXPRESSION; ANTIVIRAL ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; CELL CULTURE; CONTROLLED STUDY; DRUG POTENTIATION; GENE EXPRESSION; HEPATITIS C VIRUS; HEPATOMA CELL; HUMAN; HUMAN CELL; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; REPLICON; RNA REPLICATION; RNA TRANSLATION;

HEPATITIS C VIRUS;

EID: 33646265745     PISSN: 1743422X     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-2-1     Document Type: Article

References (41)

1. Brassard DL, Grace MJ, Bordens RW: Interferon-alpha as an immunotherapeutic protein. J Leukoc Biol 2002, 71:565-581.
2. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, Langer JA, Sheikh F, Dickensheets H, Donnelly RP: IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003, 4:69-77.
3. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J, Ostrander C, Dong D, Shin J, Presnell S, Fox B, Haldeman B, Cooper E, Taft D, Gilbert T, Grant FJ, Tackett M, Krivan W, McKnight G, Clegg C, Foster D, Klucher KM: IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003, 4:63-68.
4. Chen J, Baig E, Fish EN: Diversity and relatedness among the type I interferons. J Interferon Cytokine Res 2004, 24:687-698.
5. Gray PW, Goeddel DV: Structure of the human immune interferon gene. Nature 1982, 298:859-863.
6. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD: How cells respond to interferons. Annu Rev Biochem 1998, 67:227-264.
7. Foster GR, Finter NB: Are all type I human interferons equivalent? J Viral Hepat 1998, 5:143-152.
8. Samuel CE: Antiviral actions of interferons. Clin Microbiol Rev 2001, 14:778-809, table of contents.
9. Darnell JEJ, Kerr IM, Stark GR: Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994, 264:1415-1421.
10. Larner A, Reich NC: Interferon signal transduction. Biotherapy 1996, 8:175-181.
11. Parmar S, Platanias LC: Interferons: mechanisms of action and clinical applications. Curr Opin Oncol 2003, 15:431-439.
12. Williams BR, Haque SJ: Interacting pathways of interferon signaling. Semin Oncol 1997, 24:S9-70-S9-77.
13. Liu KD, Gaffen SL, Goldsmith MA: JAK/STAT signaling by cytokine receptors. Curr Opin Immunol 1998, 10:271-278.
14. Der SD, Zhou A, Williams BR, Silverman RH: Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci U S A 1998, 95:15623-15628.
15. Zhu H, Zhao H, Collins CD, Eckenrode SE, Run Q, McIndoe RA, Crawford JM, Nelson DR, She JX, Liu C: Gene expression associated with interferon alfa antiviral activity in an HCV replicon cell line. Hepatology 2003, 37:1180-1188.
16. Kochs G, Haller O: Interferon-induced human MxA GTPase blocks nuclear import of Thogoto virus nucleocapsids. Proc Natl Acad Sci U S A 1999, 96:2082-2086.
17. Sen GC: Viruses and interferons. Annu Rev Microbiol 2001, 55:255-281.
18. Durbin RK, Mertz SE, Koromilas AE, Durbin JE: PKR protection against intranasal vesicular stomatitis virus infection is mouse strain dependent. Viral Immunol 2002, 15:41-51.
19. Buelens C, Bartholome EJ, Amraoui Z, Boutriaux M, Salmon I, Thielemans K, Willems F, Goldman M: Interleukin-3 and interferon beta cooperate to induce differentiation of monocytes into dendritic cells with potent helper T-cell stimulatory properties. Blood 2002, 99:993-998.
20. Marrack P, Kappler J, Mitchell T: Type I interferons keep activated T cells alive. J Exp Med 1999, 189:521-530.
21. Alter MJ: The epidemiology of acute and chronic hepatitis C. Clin Liver Dis 1997, 1:559-68, vi-vii.
22. Lechmann M, Liang TJ: Vaccine development for hepatitis C. Semin Liver Dis 2000, 20:211-226.
23. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FLJ, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982.
24. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
25. Pawlotsky JM: The nature of interferon-alpha resistance in hepatitis C virus infection. Curr Opin Infect Dis 2003, 16:587-592.
26. Matthews SJ, McCoy C: Peginterferon alfa-2a: a review of approved and investigational uses. Clin Ther 2004, 26:991-1025.
27. Pestka S, Langer JA, Zoon KC, Samuel CE: Interferons and their actions. Annu Rev Biochem 1987, 56:727-777.
28. Mihm S, Frese M, Meier V, Wietzke-Braun P, Scharf JG, Bartenschlager R, Ramadori G: Interferon type I gene expression in chronic hepatitis C. Lab Invest 2004, 84:1148-1159.
29. Robek MD, Boyd BS, Chisari FV: Lambda interferon inhibits hepatitis B and C virus replication. J Virol 2005, 79:3851-3854.
30. Brand S, Zitzmann K, Dambacher J, Beigel F, Olszak T, Vlotides G, Eichhorst ST, Goke B, Diepolder H, Auernhammer CJ: SOCS-1 inhibits expression of the antiviral proteins 2′,5′-OAS and MxA induced by the novel interferon-lambdas IL-28A and IL-29. Biochem Biophys Res Commun 2005, 331:543-548.
31. Nelson DR, Tu Z, Soldevila-Pico C, Abdelmalek M, Zhu H, Xu YL, Cabrera R, Liu C, Davis GL: Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. Hepatology 2003, 38:859-868.
32. Biron CA: Interferons alpha and beta as immune regulators - a new look. Immunity 2001, 14:661-664.
33. Tompkins WA: Immunomodulation and therapeutic effects of the oral use of interferon-alpha: mechanism of action. J Interferon Cytokine Res 1999, 19:817-828.
34. Girdlestone J: Regulation of HLA class I loci by interferons. Immunobiology 1995, 193:229-237.
35. Kurokohchi K, Carrington M, Mann DL, Simonis TB, Alexander-Miller MA, Feinstone SM, Akatsuka T, Berzofsky JA: Expression of HLA class I molecules and the transporter associated with antigen processing in hepatocellular carcinoma. Hepatology 1996, 23:1181-1188.
36. Guo JT, Bichko VV, Seeger C: Effect of alpha interferon on the hepatitis C virus replicon. J Virol 2001, 75:8516-8523.
37. Zhu Q, Guo JT, Seeger C: Replication of hepatitis C virus subgenomes in nonhepatic epithelial and mouse hepatoma cells. J Virol 2003, 77:9204-9210.
38. Honda M, Kaneko S, Shimazaki T, Matsushita E, Kobayashi K, Ping LH, Zhang HC, Lemon SM: Hepatitis C virus core protein induces apoptosis and impairs cell-cycle regulation in stably transformed Chinese hamster ovary cells. Hepatology 2000, 31:1351-1359.
39. Zhu H, Shang X, Terada N, Liu C: STAT3 induces anti-hepatitis C viral activity in liver cells. Biochem Biophys Res Commun 2004, 324:518-528.
40. Zhu H, Liu C: Interleukin-1 inhibits hepatitis C virus subgenomic RNA replication by activation of extracellular regulated kinase pathway. J Virol 2003, 77:5493-5498.
41. Shang XZ, Zhu H, Lin K, Tu Z, Chen J, Nelson DR, Liu C: Stabilized beta-catenin promotes hepatocyte proliferation and inhibits TNFalpha-induced apoptosis. Lab Invest 2004, 84:332-341.